Navigation Links
InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
Date:5/25/2011

forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information.  InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.  

Other factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 9, 2011 (the "Form 10-K"), and other periodic reports filed with the SEC, including but not limited to the following: (i) risks related to the uncertain, lengthy and expensive clinical development process for the company's product candidates, including having no unexpected safety, toxicology, clinical or other issues and having no unexpected clinical trial results such as unexpected new clinical data and unexpected additional analysis of existing clinical data; (ii) risks related to the regulatory process for the company's product candidates, including the possibility that the results of the proposed new 52-week Phase 3 clinical trial (ASCEND) having an FVC endpoint may not be satisfactory to the FDA for InterMune to receive regulatory approval for pirfenidone in the United States; (iii) risks related to unexpected regulatory actions or delays or government regulation generally; (iv) risks related to the company's manufacturing strategy, which relies on third-party manufacturers and which exposes InterMune to additional risks where it may lose potential revenue; (v) government, industry and general public pricing pressures; and (vi) InterMune's ability to obtain or maintain patent or other proprietary intellectual property protections.  The risks and other factors discussed above should be considered only in conne
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. InterMune Receives European Union Approval for Esbriet® (pirfenidone)
2. InterMune Reports Fourth Quarter and Full Year 2010 Financial Results and Business Highlights
3. InterMune to Present at J.P. Morgan Healthcare Conference
4. InterMune Reports Third Quarter 2010 Financial Results
5. InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS)
6. InterMune to Release Second Quarter Financial Results on July 27
7. InterMune Announces Conference Call and Webcast to Discuss Outcome of FDA Advisory Committee
8. FDA Advisory Committee Recommends Approval of InterMunes Esbriet(R) (pirfenidone) for Idiopathic Pulmonary Fibrosis
9. InterMune Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Pirfenidone
10. InterMune Reports Fourth Quarter and Full Year 2009 Financial Results and Business Highlights
11. InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... LOUIS , July 11, 2014 /PRNewswire/ ... device company, announced today the positive, cost-effective ... its innovative SPiNPerc™ procedure. The SPiNPerc endobronchial ... of a percutaneous approach to biopsy when ... Hospitals, patients and physicians experience positive financial ...
(Date:7/10/2014)... NEWS, Virginia , 11. Juli ... Hersteller von Kameras für die molekulare ... (MBI/BSGI), hat heute die CE-Zulassung für ... dem CE-Zeichen kann Dilon das Produkt ... Vertriebsbereich auf den Großteil der europäischen ...
(Date:7/10/2014)... , July 10, 2014  RESMED INC. (NYSE: ... fourth quarter and fiscal year ended June 30, 2014 results ... Exchange market close. A press release with ResMed,s results will ... company will host a webcast to discuss operating results and ... begin at 1:30 p.m. US Pacific Time and the live ...
Breaking Medicine Technology:Veran Medical Publishes Lung Cancer Patient Management Study 2Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... Group, an international generic pharmaceuticals company, today announced ... Extended-Release Tablets, 2mg, 4mg, 6mg, 8mg and 12mg, ... believes this is the first generic Requip® XL ... has commenced.   Requip® XL, 2mg, 4mg, ...
... Mass. and TORONTO, May 18, 2012 Generex ... members have joined the Scientific Advisory Board (SAB) ... the company,s AE37 breast cancer vaccine.  The following ... N. Hortobagyi, MD, FACP (University of Texas MD ...
Cached Medicine Technology:Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets) 2Generex Augments Antigen Express Scientific Advisory Board 2Generex Augments Antigen Express Scientific Advisory Board 3Generex Augments Antigen Express Scientific Advisory Board 4
(Date:7/12/2014)... 12, 2014 Floor-grade instrument ... 4.1 out of 5. This above-average score represents ... underpinning buyer negotiation power over the three years ... Son, “during the period, surging demand for healthcare ... with new product development, have placed upward pressure ...
(Date:7/12/2014)... The largest pure occupational medicine company ... announce that it will be opening its fifth Georgia ... join four Atlanta-based Nova Medical Centers’ locations. The ... Bridge Road, and will be open from 8:30 a.m. ... Nova’s treatment philosophy of rapid return-to-work and decreased treatment ...
(Date:7/11/2014)... Recently, MagicQuinceaneraDresses.com, the popular online supplier of special ... Quinceanera dresses . The company’s new items are ... without paying a large amount of money. They are ... , The company’s online shop has become a one ... outfits. In addition to exquisite Quinceanera dresses, it also ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 The American ... America’s 55 poison centers are commending Senator Bill Nelson ... Prevention Act of 2014 on July 10, 2014. Along ... Consumer Products Safety Commission (CPSC) to enact rules requiring ... consumers. , Senate co-sponsors of the bill ...
(Date:7/11/2014)... reports that tickets to the Argentina vs. Germany World ... Brazil and Netherlands are in high demand. The ... at Estadio Nacional de Brasilia Mane Garrincha Brasila, Federal District. ... 13th at Estadio Jornalista Mario Filho - Estadio do Maracana, ... are guaranteed to be authentic and are covered by Ticket ...
Breaking Medicine News(10 mins):Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 4Health News:Nova Medical Centers To Open New Facility in Augusta, Georgia 2Health News:Cheap Quinceanera Dresses Now Available At MagicQuinceaneraDresses.com 2Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 2Health News:AAPCC Issues Statement on the Introduction of the Child Nicotine Poison Prevention Act of 2014 3Health News:Argentina vs. Germany World Cup Finals Tickets & Brazil vs. Netherlands 3rd Place World Cup Tickets Are in Huge Demand 2
... Afghanistan and Nigeria is a polio-endemic country, according to ... the indigenous polio transmission, according to the report. // ... the virus has also been announced. ,The ... phase with the next-generation vaccines targeting the two surviving ...
... Kong from buying poultry from southern China. Chicken happens to be ... One seller at a market close to the border said Hong ... to make it easier to get them through the customs. ... of three from a village in the Shataukok border area were ...
... India for the sake of low priced cosmetic surgery. ... rhinoplasty, and breast improvements are very expensive. // Over ... every year. ,Recent figures released by ... breast enlargement topped the list of cosmetic operations performed ...
... affected as a result of snoring, according to research results ... Center // in Illinois. Most women are negatively affected by ... to divorces, according to the research. As many as 10 ... tense relationship develops between the couple when one of them ...
... on the verge of path breaking news that suggests ... // Reduced vitamin D levels in the mother ... onset of this disorder, according to the research report, ... long frozen Danish samples hold the clues that will help ...
... been raised against a Food Standards Agency advertisement, ... appropriate evidence. // An investigation was ordered following ... a salt-challenge had lowered their hypertension by consuming ... that examined the case stated that there was ...
Cached Medicine News:Health News:More People Come To India For Cosmetic Surgery 2Health News:Sunny Side Up - Vitamin-D deficiency linked to Schizophrenia 2Health News:Government Advertisement Faces Criticism For Wrong Salt Claim 2
... the most useful features is the PupilFit ... mathematical analysis of the pupil images, producing ... instantaneously. The fitted circle is shown as ... proof that the measurement ismeaningful, and not ...
Dual-sided, Interhemispheric Grid Electrode with 16 Contact Leads; Cortical Grid Electrode with 16 Contact Leads; Pediatric Grid Electrode with Flex Connector, 0.5 cm spacing...
Ad-Techs Epidural Peg Electrodes feature a silicone-insulated titanium contact. To accommodate varying skull thicknesses, the post lengths range in length from 4 to 16 mm. The connecting lead wires e...
...
Medicine Products: